Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | PLEC | Q15149 | 1/20 | 0.64 |
| ▸ | CA1 | P00915 | 16/20 | 0.57 |
| ▸ | CA2 | P00918 | 16/20 | 0.57 |
| ▸ | CA9 | Q16790 | 16/20 | 0.57 |
| ▸ | CA12 | O43570 | 7/20 | 0.55 |
| ▸ | ALPL | P05186 | 1/20 | 0.54 |
| ▸ | ALPI | P09923 | 1/20 | 0.54 |
| ▸ | ALPG | P10696 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 3/20 | 0.51 |
| ▸ | DNASE1L3 | Q13609 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16103947 | 0.93 | USP2 (0.62) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL17833665 | 0.90 | MEN1 (0.49) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL10031014 | 0.89 | USP2 (0.60) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL19817548 | 0.89 | USP2 (0.60) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL14510941 | 0.88 | USP2 (0.59) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL10035689 | 0.88 | USP2 (0.59) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL13097493 | 0.85 | CA9 (0.75) | USP2CA1CA2CA9CA12 | |
| SCHEMBL19705803 | 0.83 | CA1 (0.54) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL19958456 | 0.83 | CA1 (0.54) | USP2MEN1POLBKMT2AATM | |
| SCHEMBL19817547 | 0.82 | CA1 (0.59) | USP2MEN1POLBKMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160166679-A1 | METHOD OF TREATMENT USING FOLATE CONJUGATES AND TYROSINE KINASE INHIBITORS | PURDUE RESEARCH FOUNDATION | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160166679-A1 | METHOD OF TREATMENT USING FOLATE CONJUGATES AND TYROSINE KINASE INHIBITORS | DHFR, FOLR1, FER | USP2 2489/4885MEN1 1476/4885POLB 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.